Have a feature idea you'd love to see implemented?
Let us know!
EW Edwards Lifesciences Corp
Price (delayed)
$68.02
Market cap
$40.95B
P/E Ratio
27.99
Dividend/share
N/A
EPS
$2.43
Enterprise value
$40B
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of
Highlights
The price to earnings (P/E) is 38% lower than the 5-year quarterly average of 44.8 and 21% lower than the last 4 quarters average of 35.4
The equity has grown by 17% year-on-year and by 4.5% since the previous quarter
EW's gross margin is down by 3.4% year-on-year
Key stats
What are the main financial stats of EW
Market
Valuations
Earnings
Shares outstanding
602M
Market cap
$40.95B
Enterprise value
$40B
Price to earnings (P/E)
27.99
Price to book (P/B)
5.51
Price to sales (P/S)
6.83
EV/EBIT
23.85
EV/EBITDA
21.53
EV/Sales
6.67
Revenue
$6B
EBIT
$1.68B
EBITDA
$1.86B
Free cash flow
$571.8M
Per share
Balance sheet
Liquidity
EPS
$2.43
Free cash flow per share
$0.95
Book value per share
$12.35
Revenue per share
$9.96
TBVPS
$14.17
Total assets
$10.1B
Total liabilities
$2.59B
Debt
$693M
Equity
$7.44B
Working capital
$3.3B
Debt to equity
0.09
Current ratio
3.71
Quick ratio
2.32
Net debt/EBITDA
-0.51
Margins
Efficiency
Dividend
EBITDA margin
31%
Gross margin
77%
Net margin
24.6%
Operating margin
26.3%
Return on assets
15.3%
Return on equity
21.1%
Return on invested capital
27.2%
Return on capital employed
18.9%
Return on sales
28%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EW stock price
How has the Edwards Lifesciences stock price performed over time
Intraday
-0.76%
1 week
4.41%
1 month
3.52%
1 year
-6.69%
YTD
-10.79%
QTD
3.08%
Financial performance
How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$6B
Gross profit
$4.62B
Operating income
$1.58B
Net income
$1.47B
Gross margin
77%
Net margin
24.6%
EW's revenue is up by 11% year-on-year
The operating income has grown by 9% from the previous quarter and by 8% YoY
The company's operating margin rose by 8% QoQ but it fell by 2.6% YoY
EW's gross profit is up by 7% year-on-year
Growth
What is Edwards Lifesciences's growth rate over time
Valuation
What is Edwards Lifesciences stock price valuation
P/E
27.99
P/B
5.51
P/S
6.83
EV/EBIT
23.85
EV/EBITDA
21.53
EV/Sales
6.67
The price to earnings (P/E) is 38% lower than the 5-year quarterly average of 44.8 and 21% lower than the last 4 quarters average of 35.4
The company's EPS rose by 7% YoY and by 4.3% QoQ
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 10.1 and 23% less than its last 4 quarters average of 7.2
The equity has grown by 17% year-on-year and by 4.5% since the previous quarter
The P/S is 37% below the 5-year quarterly average of 10.8 and 21% below the last 4 quarters average of 8.6
EW's revenue is up by 11% year-on-year
Efficiency
How efficient is Edwards Lifesciences business performance
Edwards Lifesciences's return on equity has decreased by 7% YoY
The company's return on sales fell by 6% YoY but it rose by 2.2% QoQ
EW's return on assets is down by 5% year-on-year
The company's return on invested capital fell by 3.5% YoY
Dividends
What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EW.
Financial health
How did Edwards Lifesciences financials performed over time
The company's current ratio rose by 18% YoY
EW's quick ratio is up by 15% year-on-year
The debt is 91% less than the equity
The company's debt to equity fell by 18% YoY and by 10% QoQ
The equity has grown by 17% year-on-year and by 4.5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.